Unibest 优贝德
← Back to patent-cliff list

泰地唑利磷酸盐

Tier C — Watch / trade

Tedizolid Phosphate · all drugs expiring in 2029 →

东亚制药株式会社
Originator
2014
First approval
2029
Expiry (public)
$0.2B *
Peak sales
化学药
Type

Targets:50S ribosomal subunit

Brand:Sivextro

Indications (approved):皮肤和皮肤结构感染、葡萄球菌感染、细菌性皮肤疾病

Regional status

US
批准上市
2014-06-20
EU
批准上市
2015-03-23
China
批准上市
2019-02-22
Japan
批准上市
2018-03-23

Synthetic routes & intermediates3 routes

Originator routes × 1Optimised (non-patent) × 2Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 3Steps 7 · Total yield 81.6 mg
Synthetic routes & intermediates Route 3
CodeCAS No.Intermediate
TEDI-005487041-08-7(R)-3-(3-fluoro-4-iodophenyl)-5-(hydroxymethyl)oxazolidin-2-one
TEDI-008856866-72-3(R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
TEDI-01097483-77-7(5-(methylsulfonyl)pyridin-2-yl)methanamine hydrochloride
TEDI-011380380-60-95-bromo-2-(2H-tetrazol-5-yl)pyridine
TEDI-018656-65-54-bromo-3-fluoroaniline
TEDI-019510729-01-8benzyl (4-bromo-3-fluorophenyl)carbamate
TEDI-020874290-59-2(4-(((benzyloxy)carbonyl)amino)-2-fluorophenyl)boronic acid
TEDI-0211220910-89-3benzyl (3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)carbamate
TEDI-0221374651-37-2ammonium 5-(5-bromopyridin-2-yl)tetrazol-2-ide
OptimisedRoute 1Steps 9 · Total yield 815 mg
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
TEDI-001372-19-03-fluoroaniline
TEDI-002149524-47-0benzyl (3-fluorophenyl)carbamate
TEDI-00360456-26-0Available(R)-oxiran-2-ylmethyl butyrate
TEDI-004149524-42-5(R)-3-(3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one
TEDI-005487041-08-7(R)-3-(3-fluoro-4-iodophenyl)-5-(hydroxymethyl)oxazolidin-2-one
TEDI-006856867-57-7(R)-3-(3-fluoro-4-(tributylstannyl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
TEDI-007380380-64-35-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine
TEDI-008856866-72-3(R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
TEDI-009624-28-22,5-dibromopyridine
TEDI-01097483-77-7(5-(methylsulfonyl)pyridin-2-yl)methanamine hydrochloride
TEDI-011380380-60-95-bromo-2-(2H-tetrazol-5-yl)pyridine
OptimisedRoute 2Steps 6 · Total yield 3.82 g
Synthetic routes & intermediates Route 2
CodeCAS No.Intermediate
TEDI-005487041-08-7(R)-3-(3-fluoro-4-iodophenyl)-5-(hydroxymethyl)oxazolidin-2-one
TEDI-011380380-60-95-bromo-2-(2H-tetrazol-5-yl)pyridine
TEDI-0121261441-79-52-fluoro-1-iodo-4-isocyanatobenzene
TEDI-013113826-06-5(R)-oxiran-2-ylmethyl 4-methylbenzenesulfonate
TEDI-014501939-82-8(R)-(3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate
TEDI-0151654754-45-6(R)-(3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl)methyl dihydrogen phosphate
TEDI-016883231-14-9(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)boronic acid
TEDI-0171654754-39-8dimethyl (6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)boronate

Frequently asked questions

What are the approved indications of Tedizolid Phosphate?

Approved indications include: 皮肤和皮肤结构感染, 葡萄球菌感染, 细菌性皮肤疾病.

When does the Tedizolid Phosphate patent expire?

Based on public sources, the Tedizolid Phosphate patent expires in 2029.

How many synthesis routes are recorded for Tedizolid Phosphate?

3 synthesis routes are recorded; the shortest is 6 steps with 3.82 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Tedizolid Phosphate intermediates?

1 intermediate CAS of Tedizolid Phosphate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Tedizolid Phosphate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24